Investisseurs

Theraclion announces 2023 financial results and continues its roadmap

Theraclion pursues its strategy and announces its 2023 revenue

Theraclion delivers its 2023 strategic objectives

First patients treated with SONOVEIN® as part of the FDA-approved pivotal study

Theraclion announces its half-year financial results for 2023 and provides an update on the execution of its strategy

Theraclion executes strategy in first half

Theraclion announces the success of its capital increase

Theraclion announces strategic partnership, capital raise and CEO appointment

Theraclion announces 2022 financial results and informs on the company’s short-term financing

FDA approval for pivotal varicose veins study with Theraclion’s SONOVEIN®

Theraclion announces results of first US trial

Theraclion reaches major milestones in 2022, paving the way for the commercial deployment of SONOVEIN®

University of Virginia (UVA) cancer center to use Theraclion’s HD technology

Theraclion successfully represented at the 8th international symposium on focused ultrasound

Last patient of first SONOVEIN® US study has been treated

New echotherapy for varicose veins partnership with Parisian region hospital wound center announced

The new strategy is paying off

A harvest of good news

95% vein occlusion rate: results presented by Dr Stalnikiewicz at Swiss Vein Days 2022

HIFU and their use in immune-oncology presented at the annual scientific meeting of the society of interventional radiology in Boston

Theraclion launches SONOVEIN® HD, its new robotic platform for veins

First patients treated with Theraclion’s SONOVEIN®in the US

Theraclion announces 1,000th treatment for varicose veins with SONOVEIN ®

2021 results in line with Theraclion’s development strategy for 2022

Theraclion announces first patient inclusion in early-stage breast cancer study

Theraclion announces the successful completion of a €6.5 million capital increase

Theraclion ready to scale up in 2022

Yann Duchesne appointed new executive chairman to lead major shift in Theraclion’s strategy

Theraclion’s is deploying its scalable robotic platform SONOVEIN® in Europe

Theraclion’s first varicose veins treatment in Hong-Kong opens perspectives in Asia

Theraclion results show strong recovery, allowing ambitious plans

FDA approves the 1st trial with Theraclion’s vein therapy in the US

Theraclion’s sales multiplied by 5 in the first half of 2021

Theraclion strengthens its Board of Directors

Bernard Sabrier and Unigestion pass the 20% threshold, proof of confidence in the company’s development

UVA Cancer Center to expand use of Theraclion’s HIFU system in cancer treatment research.

In 2020, Theraclion has succeeded a crucial step for its technology.

Theraclion’s strategy is in place for 2021 despite the impact of Covid-19 on sales revenues for 2020

Renewed investor confidence in Theraclion

Positive and differentiated results for Theraclion’s non-invasive varicose vein treatment technology revealed at the 34th AVLS

Theraclion’s 2nd generation breakthrough technology for varicose vein treatments ready to launch

Christopher S. Bödtker appointed Chairman of Theraclion

Clarification on its cash flow situation

Truffle Capital shareholding reduced to 2.4%

Revenue H1 2019

Four Systems Sales and Major Reimbursement Agreement

CE mark for the non-invasive treatment of varicose veins

€11.8 million new financing package concluded

Revenu 2018

Tübingen/Fus

Progress in Switzerland and Germany

First European podium presentation of SONOVEIN

First Half 2018 Results

Theraclion achieves key milstones in Germany

First patient in Forfait Innovation

First Echotherapy Center in Berlin

Theraclion completes first varicose veins study

Theraclion completes first varicose veins study

Sales and clinical development in Asia

First Echopulse® in Catalonia, Spain

Theraclion Accelerates its Growth in 2017

Immunotherapy breast cancer strategy

First patient treatments in Poland

First sale to Poland

First 5 Theraclion Echopulse systems delivered to China

First sales to China

Reimbursement to 15 Million covered German lives

Two sales to Eastern Europe and China

New clinical data to be presented during RSNA

Preliminary Results In the Treatment of Varicose Veins

Webinar to discuss preliminary results in veins

Information on shareholding

Theraclion makes substantial progress towards market access

Theraclion raises € 4.2 million

Study in non-invasive varicose vein treatment and the launch of a capital increase

Exclusive Distribution Agreement with EDAP TMS France

Theraclion Extends Market Access and Regulatory Approval

Key markets Germany and Hong Kong, China

f First Clinical Trial Combining Echotherapy and Imunotherapy to Treat Metastatic Breast Cancer

Promising clinical trial results in a new thyroid indication

Conference Call on First Immuno-Oncology Metastatic Breast Cancer Trial

New clinical study results (Tübingen)

Theraclion Announces Expansion of Echotherapy Reimbursement Coverage to 14 Million Lives in Germany

World’s largest & first Asian study

Improved Outcomes Compared to Surgical

First oncological veterinary patient

Presentation of U.S. clinical data

Joint Venture in China

Long-term Echopulse® results in breast fibroadenoma

2017 German Stevie Awards

U.S. pivotal multicentre FDA Study

French authorities grant derogation reimbursement

Sales UK

New Clinical Data Strongly Support the Safety and Efficacy

18th Annual Rodman & Renshaw Global Investment Conference

Major German Insurance Company in AOK

First Data Generated in U.S.

First acquisition of Echopulse® in Switzerland

First agreement in Italy

HAS first positive feedback to Forfait Innovation

Sales in Hamburg

New clinical study results

De nouveaux résultats d’études cliniques

+115% growth in treatment numbers

Large Chinese Biotech & Pharmaceutical group acquires 8%

Sales to German Nuclear Medicine Practice

Extended reimbursement in Germany

Treatment number growth

First Patients in the UK

Theraclion’s growth continues in 2016

Submission for « Forfait Innovation »

Annual Results 2015

BEAMOTION marquée CE

First European commercial agreements in Thyroid

Start of clinical trials

First reference site in Asia:

Theraclion’s managers and employees invest in capital equity

First Sales in Egypt

Theraclion receives an additional financing

German Patients Covered

Business Development Director for Asia

Signature of Equity Line

Further reimbursements in Germany

Publication on Thyroid

Asia & Nominations

Publication in JTU

Sales Agreement and First International Publication

Nomination and Sales

Nomination of a VP Business Development

First reimbursements in Germany

Strengthening management team

Publication in Intl J of Hyperthermia

Publication in J. of Therap. Ultrasound

Theraclion receives €900 thousand from Bpifrance’s “Industrial Strategic Innovation” program

Theraclion obtains FDA approval for IDE

FDA approval for IDE in USA for Breast Fibroadenoma

CE Mark breast fibroadenoma

CE marking approval for Breast Fibroadenoma

First successfully treated breast fibroadenomas in two patients

First succesful treatments of patients for Breast fibroadenoma

Frost & Sullivan European Ultrasound Technology Innovation Award

Theraclion receives the Frost & Sullivan European Ultrasound Technology Innovation Award